Open an account

Armata Pharmaceuticals

ARMP · NYSE American

$3.20+$0.13 (+4.23%)TodayMarket closed ·
Prev close $3.07

ARMP analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $17.85 (+457.8% upside)

Low
$15.15
Now
$3.20
High
$21.00

Upgrades and downgrades

The latest rating actions, newest first

ARMP analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 23, 2026MaintainsBuy
HC Wainwright & Co.Feb 23, 2026MaintainsBuy
Jones TradingJan 5, 2026InitiatesBuy

The case for and against

Updated May 1, 2025

Bull case

Armata Pharmaceuticals Inc. is advancing its proprietary bacteriophage-based technology, focusing on treating antibiotic-resistant bacterial infections, which aligns with the increasing demand for innovative therapies within the medical community. The company has made significant progress by completing enrollment in key clinical trials, such as the Phase 2 Tailwind study and the Phase 1b/2a diSARM study, which are critical for generating pivotal data that could enhance the commercial viability of its therapies. Preliminary data suggests that the lead candidate, AP-PA02, demonstrates effective outcomes and a favorable safety profile, indicating potential market disruption and the ability to meet the urgent needs of healthcare professionals and patients alike.

Bear case

The financial outlook for Armata Pharmaceuticals is negatively impacted by the substantial risks associated with the potential failure of clinical trials, which could hinder the company's ability to deliver effective therapies. Moreover, the company faces challenges in securing adequate funding, essential for progressing its drug candidates through the development stages, which raises concerns about its financial stability and operational continuity. Additionally, issues related to sample sizes and patient data in trials have raised doubts regarding the statistical significance of results, further complicating Armata's path to successful product development and market entry.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.